DnB Asset Management AS increased its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 39.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 79,619 shares of the medical research company's stock after purchasing an additional 22,450 shares during the quarter. DnB Asset Management AS's holdings in IQVIA were worth $15,646,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also recently made changes to their positions in the business. Synergy Asset Management LLC bought a new stake in IQVIA in the fourth quarter valued at $33,000. Lee Danner & Bass Inc. purchased a new position in shares of IQVIA during the fourth quarter valued at about $44,000. Zions Bancorporation N.A. raised its stake in IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after buying an additional 85 shares in the last quarter. Versant Capital Management Inc lifted its holdings in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after buying an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. bought a new stake in IQVIA during the 4th quarter valued at approximately $60,000. 89.62% of the stock is owned by hedge funds and other institutional investors.
IQVIA Stock Performance
Shares of IQV stock traded down $1.12 on Monday, reaching $176.28. The stock had a trading volume of 2,234,715 shares, compared to its average volume of 1,303,021. The stock has a market cap of $31.08 billion, a P/E ratio of 23.50, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $169.54 and a 1 year high of $253.84. The company has a 50 day simple moving average of $193.15 and a 200 day simple moving average of $206.05.
IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on the company. Morgan Stanley raised their target price on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Robert W. Baird dropped their target price on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, January 21st. William Blair reiterated an "outperform" rating on shares of IQVIA in a research note on Wednesday, December 11th. UBS Group cut their price objective on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Finally, Stephens began coverage on shares of IQVIA in a report on Friday, December 20th. They set an "overweight" rating and a $250.00 target price for the company. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, IQVIA presently has a consensus rating of "Moderate Buy" and an average price target of $249.05.
Check Out Our Latest Report on IQV
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
